NeuroBo Pharmaceuticals (NRBO) Competitors $0.61 -0.03 (-4.65%) As of 07/30/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock NRBO vs. WVFC, JFU, SAIH, ANY, GLBZ, CARV, NCPL, MIGI, MCVT, and SHFSShould you be buying NeuroBo Pharmaceuticals stock or one of its competitors? The main competitors of NeuroBo Pharmaceuticals include WVS Financial (WVFC), 9F (JFU), SAIHEAT (SAIH), Sphere 3D (ANY), Glen Burnie Bancorp (GLBZ), Carver Bancorp (CARV), Netcapital (NCPL), Mawson Infrastructure Group (MIGI), Mill City Ventures III (MCVT), and SHF (SHFS). These companies are all part of the "banking" industry. NeuroBo Pharmaceuticals vs. Its Competitors WVS Financial 9F SAIHEAT Sphere 3D Glen Burnie Bancorp Carver Bancorp Netcapital Mawson Infrastructure Group Mill City Ventures III SHF WVS Financial (NASDAQ:WVFC) and NeuroBo Pharmaceuticals (NASDAQ:NRBO) are both small-cap banking companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability. Is WVFC or NRBO more profitable? WVS Financial has a net margin of 9.50% compared to NeuroBo Pharmaceuticals' net margin of 0.00%. WVS Financial's return on equity of 12.31% beat NeuroBo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets WVS Financial9.50% 12.31% 1.29% NeuroBo Pharmaceuticals N/A -189.12%-122.31% Does the media prefer WVFC or NRBO? In the previous week, WVS Financial's average media sentiment score of 0.00 equaled NeuroBo Pharmaceuticals'average media sentiment score. Company Overall Sentiment WVS Financial Neutral NeuroBo Pharmaceuticals Neutral Which has more volatility & risk, WVFC or NRBO? WVS Financial has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500. Comparatively, NeuroBo Pharmaceuticals has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500. Which has preferable earnings & valuation, WVFC or NRBO? WVS Financial has higher revenue and earnings than NeuroBo Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWVS Financial$5.13M4.49$1.38M$1.0511.58NeuroBo PharmaceuticalsN/AN/A-$12.47MN/AN/A Do insiders & institutionals hold more shares of WVFC or NRBO? 6.3% of WVS Financial shares are owned by institutional investors. Comparatively, 1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. 13.5% of WVS Financial shares are owned by company insiders. Comparatively, 1.1% of NeuroBo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryWVS Financial beats NeuroBo Pharmaceuticals on 8 of the 8 factors compared between the two stocks. Get NeuroBo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRBO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRBO vs. The Competition Export to ExcelMetricNeuroBo PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.21M$763.52M$5.47B$9.53BDividend YieldN/A4.84%4.74%4.08%P/E RatioN/A1.3428.6723.80Price / SalesN/A25.20422.2688.08Price / CashN/A19.5635.4557.96Price / Book0.406.778.275.55Net Income-$12.47M-$4.28M$3.24B$259.03M7 Day Performance-14.18%-3.02%-3.63%-4.56%1 Month Performance-6.91%1.89%4.40%4.49%1 Year Performance-84.80%16.28%25.97%18.05% NeuroBo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRBONeuroBo PharmaceuticalsN/A$0.61-4.6%N/A-84.0%$5.21MN/A0.0010Gap UpWVFCWVS FinancialN/A$12.20-2.6%N/A-0.7%$23.11M$5.13M12.4520Gap DownJFU9FN/A$1.65+2.5%N/A-18.6%$19.42M$58.09M0.00740Gap UpSAIHSAIHEATN/A$10.77-6.6%N/AN/A$18.85M$5.54M0.0037Gap DownANYSphere 3D1.4191 of 5 stars$0.67-0.7%$3.00+349.8%-49.0%$17.65M$12.48M-1.1720Short Interest ↑Gap DownGLBZGlen Burnie Bancorp1.1762 of 5 stars$5.22-1.6%N/A-6.4%$15.13M$11.69M522.0280Earnings ReportShort Interest ↑Gap UpCARVCarver Bancorp0.0765 of 5 stars$2.69+6.3%N/A+3.4%$13.94M$37.37M-1.04110Short Interest ↑NCPLNetcapital0.3929 of 5 stars$3.07+2.1%N/A-26.9%$12.05M$4.95M-0.15N/AUpcoming EarningsMIGIMawson Infrastructure Group0.1802 of 5 stars$0.58-4.0%N/A-61.8%$11.29M$59.26M-0.3940News CoverageShort Interest ↑MCVTMill City Ventures III2.008 of 5 stars$1.76-0.3%N/A+91.8%$10.64M$3.30M9.242Gap UpSHFSSHF0.3438 of 5 stars$3.42-3.8%N/A-79.9%$9.49M$15.24M1.003Short Interest ↑Gap Down Related Companies and Tools Related Companies WVS Financial Alternatives 9F Alternatives SAIHEAT Alternatives Sphere 3D Alternatives Glen Burnie Bancorp Alternatives Carver Bancorp Alternatives Netcapital Alternatives Mawson Infrastructure Group Alternatives Mill City Ventures III Alternatives SHF Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRBO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroBo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
